EDAP TMS Confirms Success of HIFU With Ablatherm at the 20th Congress of the European Association of Urology, Istanbul

EDAP TMS Confirms Success of HIFU With Ablatherm at the 20th
Congress of the European Association of Urology, Istanbul
Studies at 8 Years Show Lower Side Effects, Preserved Quality of Life



LYON, France, March 24  /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP),
today confirms the success of HIFU with Ablatherm at the 20th Congress of the
European Association of Urology (E.A.U.), held March 16-19, 2005 in Istanbul. 
The Congress represents the pan-European urological community accounting for
more than 16,000 members and is considered one of the year's keynote events
with more than 7,000 attendees.

Ablatherm users presented the latest clinical results obtained using EDAP's
HIFU technology for the treatment of prostate cancer.  Dr. Stefan Thuroff, from
Harlaching Hospital, Munich, Germany, presented an eight-year follow-up study
of more than 1,000 patients treated with Ablatherm.  The results showed no
severe systemic side effects thus preserving the quality of life for the
patients treated with Ablatherm.  The study confirmed sustained clinical
results at eight years and demonstrated that HIFU treatment does not exclude
other therapeutic options afterwards.

Dr. Albert Gelet, from Edouard Herriot Hospital, Lyon, France, further
validated the success rates of HIFU applied to patients who failed radiotherapy
treatment.  Based on a study of more than 100 patients treated, with an average
follow-up of 15.7 months, Dr. Gelet's results showed an 84% success rate
(negative biopsy and PSA below 0.5) with no rectal damage under dedicated
parameters.  The HIFU-related side effects were statistically lower than the
side effects reported after other types of salvage therapy.

Hugues de Bantel, Chief Executive Officer of EDAP TMS, commented: "With these
positive and long-term results presented during scientific sessions, the EDAP
booth was well attended.  Urologists showed a true interest in Ablatherm and
its technology.  While discussing the technology with opinion leaders who have
been using the Ablatherm for years, urologists clearly showed they were
convinced of the success and benefits of this therapy based on the number of
patients treated to date with Ablatherm, the number of peer reviewed articles
published specifically on HIFU with Ablatherm and the now more than 63 clinical
sites using Ablatherm.  Based on the activity and response at the Congress, we
remain confident in our continued growth rates through increased patient demand
at existing clinical sites as well as additional installations of Ablatherm
units in a number of prospective sites.

During the E.A.U. Congress, a group of leading European urologists from key
markets including Germany, Belgium, the UK, Italy, and France launched the
European HIFU Club to help grow understanding and support of HIFU technology by
monitoring its developments and progress and by educating the urology community
about its benefits, its clinical applications, patient selection and follow-up.
 The Club will serve as a forum for current HIFU users to exchange views and
discuss ways of optimizing treatment outcomes.

Pr. Pierre Teillac, General Secretary of the E.A.U., commented: "We have seen
the use of HIFU technology for the treatment of localized prostate cancer
spreading rapidly across Europe over the last few years.  The creation of a
HIFU Club where clinical experience and knowledge can be shared within the
urology community and beyond was well overdue, and I strongly welcome this
initiative."

Dr. Thuroff of Germany, added: "HIFU technology for the treatment of prostate
cancer is very promising, as is demonstrated by the high rate of success that
we experienced in Munich.  HIFU will not outdate other, more established,
therapies overnight, and it is today mainly targeted at specific groups of
patients.  However, it dramatically broadens the range of treatment options."

Hugues de Bantel Chief Executive Officer of EDAP TMS, concluded: "The launch of
a European HIFU Club, initiated and supported by the European Association of
Urology, further validates the recognition of HIFU technology as a therapeutic
option for localized prostate cancer by the medical community.  We are very
enthusiastic about this initiative as it will help spread the understanding of
HIFU technology to a wider audience."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically
proven choice for High Intensity Focused Ultrasound (HIFU) treatment of
localized prostate cancer.  HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side effects.  The
company is also developing this technology for the treatment of certain other
types of tumors.  EDAP TMS S.A. also produces and commercializes medical
equipment for treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL).

For more information on the Company, contact the Investor Relations Dept by
phone at [phone] or see the Company's Web site at:
http://www.edap-tms.com/ .

This press release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties.  These include
statements regarding the Company's growth and expansion plans.  Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in the forward-looking statements.  Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission.

   CONTACT:  EDAP TMS S.A.
             Hugues de Bantel - Philippe Chauveau
             Blandine Confort
             [phone]

             Halliburton Investor Relations
             Matt Kreps - Geralyn DeBusk
             972 458 8000


DATASOURCE: EDAP TMS S.A.



CONTACT:  Hugues de Bantel, Philippe Chauveau, or Blandine Confort, all

of EDAP TMS S.A., [phone]; or Matt Kreps or Geralyn DeBusk, both of

Halliburton Investor Relations, [phone], for EDAP TMS S.A.



Web site:  http://www.edap-tms.com/ 

Copyright